Method for breast cancer recurrence prediction under endocrine treatment

A method for treating a patient having an estrogen receptor positive and HER2 negative breast tumor, the method comprising:

• determining whether the patient will benefit from cytotoxic chemotherapy by:
• (1) determining in a sample from the tumor the RNA expression level values of a set of marker genes, the set of marker genes comprising RACGAP1 and at least two of the following genes:
• BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP;
• (2) combining the expression level values determined in step (1) to yield a test combined score;
• and
• administering a treatment regimen comprising a cytotoxic chemotherapy to the patient if the test combined score exceeds a reference combined score, or
• administering a treatment regimen comprising a non-cytotoxic therapy to the patient if the test combined score does not exceed the reference combined score.

A method for treating a patient having an estrogen receptor positive and HER2 negative breast tumor, the method comprising:

• determining whether the patient will benefit from cytotoxic chemotherapy by:
• (1) determining in a sample from the tumor the RNA expression level values of a set of marker genes, the set of marker genes comprising RACGAP1 and at least two of the following genes:
• UBE2C, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP;
• (2) combining the expression level values determined in step (1) to yield a test combined score;
• and
• administering a treatment regimen comprising a cytotoxic chemotherapy to the patient if the test combined score exceeds a reference combined score, or
• administering a treatment regimen comprising a non-cytotoxic therapy to the patient if the test combined score does not exceed the reference combined score.